UNSPSC 51334205: Zotepine

This classification denotes a serotonin antagonist and dopamine antagonist with the molecular formula C18H18ClNOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U29O83JAZW, chemically known as 2-chloro-11-(2-dimethylaminoethoxy)-dibenzo(b,f)thiepine but generally known as zotepine, which bears US NIH Compound Identifier 5736. European Medicines Agency schedules Zotepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00191MIG.

UNSPSC 51334205 Zotepine, a Commodity code, nominally names a single antipsychotic drug but in practice state and local solicitations under this code are tagging diverse pharmaceutical procurement — from naloxone and drug deactivation systems for community health, to generic multi-source pharmaceuticals and over-the-counter products distributed through cooperative purchasing networks, to exploratory direct-to-manufacturer prescription programs. The work being solicited ranges from supply agreements with authorized wholesalers for multiple pharmaceutical products to facility-level purchases of specific therapeutics and harm-reduction equipment. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and cooperative purchasing alliances spanning multiple states (Minnesota Multistate Cooperative Purchasing Alliance administering contracts for participating state and local government facilities including Oregon).

Recent activity concentrates in Florida, Texas, and Minnesota, with Seminole County soliciting an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, and the Minnesota Multistate Cooperative Purchasing Alliance issuing an RFP (S1070000015802, due March 26, 2026) to establish multiple-award contracts for generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.). The Texas HHS Commission posted a Request for Information (HHS0017013, April 3, 2026) to explore vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling early-stage development of alternative procurement models for state pharmacy benefit programs. The code shows active engagement by health departments and purchasing consortia but reflects broader pharmaceutical commodity sourcing rather than zotepine-specific demand.